Department of Respiratory Medicine, University Hospital Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Integrated Research and Treatment Center (IFB) Adiposity Diseases, University Medical Center Leipzig, 04013, Leipzig, Germany.
Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1081-1092. doi: 10.1007/s00259-020-05056-7. Epub 2020 Oct 3.
Pulmonary hypertension (PH) is characterized by a progressive remodelling of the pulmonary vasculature resulting in right heart failure and eventually death. The serotonin transporter (SERT) may be involved in the pathogenesis of PH in patients with chronic-obstructive pulmonary disease (COPD). This study investigated for the first time the SERT in vivo availability in the lungs of patients with COPD and PH (COPD+PH).
SERT availability was assessed using SERT-selective [C]DASB and positron emission tomography/computed tomography (PET/CT) with dynamic acquisition over 30 min in 4 groups of 5 participants each: COPD, COPD+PH, pulmonary arterial hypertension, and a healthy control (HC). Time activity curves were generated based on a volume of interest within the middle lobe. Tissue-to-blood concentration ratios after 25 to 30 min (TTBR) served as receptor parameter for group comparison and were corrected for lung tissue attenuation. Participants underwent comprehensive pulmonary workup. Statistical analysis included group comparisons and correlation analysis.
[C]DASB uptake peak values did not differ among the cohorts after adjusting for lung tissue attenuation, suggesting equal radiotracer delivery. Both the COPD and COPD+PH cohort showed significantly lower TTBR values after correction for lung attenuation than HC. Attenuation corrected TTBR values were significantly higher in the COPD+PH cohort than those in the COPD cohort and higher in non-smokers than in smokers. They positively correlated with invasively measured severity of PH and inversely with airflow limitation and emphysema. Considering all COPD patients ± PH, they positively correlated with right heart strain (NT-proBNP).
By applying [C]DASB and PET/CT, semiquantitative measures of SERT availability are demonstrated in the lung vasculature of patients with COPD and/or PH. COPD patients who developed PH show increased pulmonary [C]DASB uptake compared to COPD patients without PH indicating an implication of pulmonary SERT in the development of PH in COPD patients.
肺动脉高压(PH)的特征是肺血管进行性重塑,导致右心衰竭,最终导致死亡。5-羟色胺转运体(SERT)可能与慢性阻塞性肺疾病(COPD)患者 PH 的发病机制有关。本研究首次在 COPD 合并 PH(COPD+PH)患者的肺部研究 SERT 的体内可用性。
使用 SERT 选择性[C]DASB 和正电子发射断层扫描/计算机断层扫描(PET/CT),对每组 5 名参与者进行 30 分钟的动态采集,评估 SERT 可用性。根据中肺叶的感兴趣区生成时间活动曲线。在 25 到 30 分钟后(TTBR),组织与血液浓度比作为组间比较的受体参数,并对肺组织衰减进行校正。参与者接受了全面的肺部检查。统计分析包括组间比较和相关性分析。
调整肺组织衰减后,[C]DASB 摄取峰值在各组之间没有差异,表明放射性示踪剂输送相等。与 HC 相比,COPD 和 COPD+PH 组经肺衰减校正后的 TTBR 值明显降低。COPD+PH 组经肺衰减校正后的 TTBR 值明显高于 COPD 组,且在不吸烟者中高于吸烟者。它们与侵入性测量的 PH 严重程度呈正相关,与气流受限和肺气肿呈负相关。考虑到所有 COPD 患者合并/不合并 PH,它们与右心应变(NT-proBNP)呈正相关。
通过应用[C]DASB 和 PET/CT,在 COPD 和/或 PH 患者的肺血管中证明了 SERT 可用性的半定量测量。与没有 PH 的 COPD 患者相比,患有 PH 的 COPD 患者的肺部[C]DASB 摄取增加,表明 SERT 可能参与了 COPD 患者 PH 的发生。